PB0884 - Development of a platform to study thrombogenicity of clinically-used stents

Monday, June 26, 2023

18:30 – 19:30 ET

Room: Exhibition

Presenting Author(s)

KJ

Kim JOUFFROY, DVM (she/her/hers)

PhD student
University of Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, F-67065 Strasbourg, France
68 000 Colmar, Alsace, France

Co-Author(s)

AK

Axelle KERN, MSc

PhD student
University of Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, F-67065 Strasbourg, France
STRASBOURG, Alsace, France
YK

Yevgeniy Kreinin

PhD student
2Department of Biomedical Engineering Technion, Israel Institute of Technology, Haifa, Israel
Haifa, Hefa, Israel
RP

Raoul Pop

Hospital practitioner
Interventional Neuroradiology Department, Strasbourg University Hospitals, Strasbourg, France
Strasbourg, Alsace, France
NK

Netanel Korin

Associate professor
Department of Biomedical Engineering Technion, Israel Institute of Technology, Haifa, Israel
Haifa, Hefa, Israel
LC

Lise Charle

Technician
1Université de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, F-67065 Strasbourg, France
Strasbourg, Alsace, France
PM

Pierre Mangin

Research Director
Université de Strasbourg, INSERM, EFS Grand Est, BPPS UMR-S1255, FMTS, F-67065 Strasbourg, France
Strasbourg, Alsace, France

Background: A tight stenosis or occlusion of an artery can result in serious ischemic events such as myocardial infarction, stroke or obliterating arteriopathy of the lower limbs. Angioplasty with stent implantation aims to reopen an artery, to improve the recanalization rates and the clinical outcomes in patients. Stent thrombosis (ST) is a life-threatening complication of angioplasty with stenting. The thrombogenic potential of stents is well-known and reducing it might lower the incidence of ST. There is a lack of reliable in vitro models to assess the thrombogenicity of clinically-used stents.

Aims: To develop a platform to assess the intrinsic thrombogenicity of clinically-used stents.

Methods: We developed an on-scale macrofluidic flow chamber mimicking different human vessels, including the carotid, femoral and coronary arteries. The flow chamber is inserted in a circular closed flow system allowing to investigate the thrombogenicity of clinically-used stents. Hemodynamic profile is characterized using computational fluid dynamics (CFD) and platelet aggregation is studied by fluorescence and scanning electron microscopy (SEM).

Results: Real-time video-macroscopy showed that hirudinated human whole blood perfused at relevant wall shear rates found in the human carotid and femoral arteries results in an accumulation of flowing platelets on all clinically-used stents evaluated, including Wallstent, Casper and Lifestent. SEM indicated that adhering platelets were activated, as indicated by their morphological modifications. Thrombus formation did not form homogenously on the stent surface with a preferential accumulation at the crossing of the struts. CFD allowed to finely characterize the flow profile in the most thrombogenic regions.

Conclusion(s): We developed a macrofluidic model that contains a flow chamber which can mimic any human vessel, and that represents a platform to evaluate the thrombogenicity of stents in development or used in clinic. Such a model can help to develop less thrombogenic stents.